The expression pattern of systemically injected AAV9 in the developing mouse retina is determined by age

Molecular Therapy

Volumn 23, Issue 2, 2015, Pages 290-296

  Byrne, Leah C ^a,b   Lin, Yvonne J ^a   Lee, Trevor ^a   Schaffer, David V ^a,b   Flannery, John G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b University of California   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENO ASSOCIATED VIRUS SEROTYPE 9; CELL PROTEIN; COLLAGEN TYPE 4; MFSD2A PROTEIN; PROTEIN ZO1; UNCLASSIFIED DRUG; VIRUS VECTOR;

AGE; ANIMAL CELL; ARTICLE; BLOOD BRAIN BARRIER; BLOOD RETINA BARRIER; CELL MATURATION; CELL POPULATION; CONTROLLED STUDY; GENE EXPRESSION; MOUSE; MUELLER CELL; NEWBORN; NONHUMAN; PIGMENT EPITHELIUM; PROTEIN EXPRESSION; PROTEIN FUNCTION; RETINA AMACRINE CELL; RETINA BIPOLAR GANGLION CELL; RETINA BLOOD VESSEL; RETINA CONE; RETINA DEGENERATION; RETINA DEVELOPMENT; RETINA GANGLION CELL; RETINA HORIZONTAL NERVE CELL; SIGNAL TRANSDUCTION; TIGHT JUNCTION; TRANSCYTOSIS; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS PARTICLE; ADMINISTRATION AND DOSAGE; ANIMAL; BRAIN; CLASSIFICATION; DEPENDOPARVOVIRUS; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; REPORTER GENE; RETINA;

MUS;

AGE FACTORS; ANIMALS; BRAIN; DEPENDOVIRUS; GENE EXPRESSION; GENES, REPORTER; GENETIC VECTORS; INJECTIONS, INTRAVENOUS; MICE; RETINA; RETINAL VESSELS; TRANSDUCTION, GENETIC; TRANSGENES;

EID: 84922126140     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2014.181     Document Type: Article

References (20)

1. Bostick B, Ghosh A, Yue Y, Long C and Duan D. (2007). Systemic AAV- 9 transduction in mice is influenced by animal age but not by the route of administration. Gene Ther 14: 1605-1609
2. Rahim AA, Wong AM, Hoefer K, Buckley SM, Mattar CN, Cheng SH., et al. (2011). Intravenous administration of AAV2/9 to the fetal and neonatal mouse leads to differential targeting of CNS cell types and extensive transduction of the nervous system. FASEB J 25: 3505-3518
3. Dalkara D, Byrne LC, Lee T, Hoffmann NV, Schaffer DV and Flannery JG. (2012). Enhanced gene delivery to the neonatal retina through systemic administration of tyrosine-mutated AAV9. Gene Ther 19: 176-181
4. Joussemet B, Belbellaa B, Mendes-Madeira A, Bucher T, Briot-Nivard D, Dubreil L., et al. (2011). Neonatal systemic delivery of scAAV9 in rodents and large animals results in gene transfer to RPE cells in the retina. Exp Eye Res 93: 491-502
5. Mattar CN, Waddington SN, Biswas A, Johana N, Ng, XW, Fisk AS., et al. (2013). Systemic delivery of scAAV9 in fetal macaques facilitates neuronal transduction of the central and peripheral nervous systems. Gene Ther 20: 69-83
6. Petrs-Silva H, Dinculescu A, Li Q, Min SH, Chiodo V, Pang JJ., et al. (2009). Highefficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors. Mol Ther 17: 463-471
7. Fruttiger M. (2007). Development of the retinal vasculature. Angiogenesis 10: 77-88
8. Provis JM. (2001). Development of the primate retinal vasculature. Prog Retin Eye Res 20: 799-821
9. Cepko CL, Austin CP, Yang X, Alexiades M and Ezzeddine D. (1996). Cell fate determination in the vertebrate retina. Proc Natl Acad Sci U S A 93: 589-595
10. Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM and Kaspar BK. (2009). Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 27: 59-65
11. Nguyen LN, Ma D, Shui G, Wong P, Cazenave-Gassiot A, Zhang X., et al. (2014). Mfsd2a is a transporter for the essential omega-3 fatty acid docosahexaenoic acid. Nature 509: 503-506
12. Ben-Zvi A, Lacoste B, Kur E, Andreone BJ, Mayshar Y, Yan H., et al. (2014). Mfsd2a is critical for the formation and function of the blood-brain barrier. Nature 509: 507-511
13. Bowes C, Li T, Danciger M, Baxter LC, Applebury ML and Farber DB. (1990). Retinal degeneration in the rd mouse is caused by a defect in the beta subunit of rod cGMP-phosphodiesterase. Nature 347: 677-680
14. Boutin S, Monteilhet V, Veron P, Leborgne C, Benveniste O, Montus MF., et al. (2010). Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther 21: 704-712
15. Li Q, Miller R, Han PY, Pang J, Dinculescu A, Chiodo V., et al. (2008). Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential. Mol Vis 14: 1760-1769
16. Shen S, Bryant KD, Brown SM, Randell SH and Asokan A. (2011). Terminal N-linked galactose is the primary receptor for adeno-associated virus 9. J Biol Chem 286: 13532-13540
17. Bell CL, Vandenberghe LH, Bell P, Limberis MP, Gao GP, Van Vliet K., et al. (2011). The AAV9 receptor and its modification to improve in vivo lung gene transfer in mice. J Clin Invest 121: 2427-2435
18. Di Pasquale G and Chiorini JA. (2006). AAV transcytosis through barrier epithelia and endothelium. Mol Ther 13: 506-516
19. Grieger JC, Choi VW and Samulski RJ. (2006). Production and characterization of adeno-associated viral vectors. Nat Protoc 1: 1412-1428
20. Aurnhammer C, Haase M, Muether N, Hausl M, Rauschhuber C, Huber I., et al. (2012). Universal real-time PCR for the detection and quantification of adenoassociated virus serotype 2-derived inverted terminal repeat sequences. Hum Gene Ther Methods 23: 18-28